Whitehawk Therapeutics (NASDAQ:WHWK) Posts Quarterly Earnings Results

Whitehawk Therapeutics (NASDAQ:WHWK) released its earnings results on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, FiscalAI reports.

Whitehawk Therapeutics Trading Up 2.5%

Shares of WHWK opened at $4.11 on Thursday. The company has a market cap of $193.70 million, a price-to-earnings ratio of 29.36 and a beta of 0.51. The business’s fifty day simple moving average is $2.96 and its two-hundred day simple moving average is $2.45. Whitehawk Therapeutics has a 12 month low of $1.39 and a 12 month high of $4.48.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Monday, December 29th. Oppenheimer assumed coverage on Whitehawk Therapeutics in a research note on Thursday, February 5th. They issued an “outperform” rating and a $6.00 target price on the stock. Finally, JonesTrading began coverage on Whitehawk Therapeutics in a report on Monday, December 22nd. They set a “buy” rating and a $7.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $6.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Quadrature Capital Ltd bought a new stake in Whitehawk Therapeutics in the 4th quarter worth about $28,000. ABG Innovation Capital Partners III GP Ltd bought a new position in Whitehawk Therapeutics during the 3rd quarter valued at about $51,000. Dimensional Fund Advisors LP bought a new position in Whitehawk Therapeutics during the 3rd quarter valued at about $84,000. Marshall Wace LLP purchased a new stake in shares of Whitehawk Therapeutics during the 4th quarter valued at about $164,000. Finally, Jane Street Group LLC grew its stake in shares of Whitehawk Therapeutics by 177.3% in the fourth quarter. Jane Street Group LLC now owns 69,931 shares of the company’s stock worth $169,000 after acquiring an additional 44,716 shares during the period. 52.08% of the stock is owned by institutional investors.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.